Drug makers may commit to follow-up studies, but few are new- STAT

Drug makers may commit to follow-up studies, but few are new- STAT

More reads

• After FDA approval, drug makers often commit to follow-up studies. Few are new, a review finds. (STAT Plus)
• How Big Pharma suppresses biosimilars. (Wall Street Journal)
• Top biotech investor looking beyond the 'sexy' parts of healthcare as he places his next bets. (Business Insider)
• Krystal Biotech shares rise after skin drug gets expedited review from FDA. (MarketWatch)